Literature DB >> 23399811

Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging.

Verena Hartung-Knemeyer1, Karsten J Beiderwellen, Christian Buchbender, Hilmar Kuehl, Thomas C Lauenstein, Andreas Bockisch, Thorsten D Poeppel.   

Abstract

OBJECTIVES: In integrated positron emission tomography (PET)/magnetic resonance imaging (MRI), the PET data acquisition is performed simultaneously to the magnetic resonance data acquisition, leaving latitude for the duration of PET acquisition time. This establishes emission time as an important parameter in forthcoming PET/MRI protocols because it is one of the key factors determining PET image quality. Thus, the purpose of the current study was to identify optimal duration of PET acquisition time in PET/MRI.
MATERIALS AND METHODS: A total of 22 consecutive patients (7 men, 15 women) underwent fluorine-18-labeled fluorodeoxyglucose (18[F]FDG) PET/MRI after clinical PET/computed tomography. Positron emission tomography/magnetic resonance scans were acquired for 8 minutes per bed position (mpb). Positron emission tomography was extracted to reconstruct images with 2, 4, 6, and 8 mpb for each patient. Visual and quantitative approaches were used to assess image quality and lesion detectability for each image. For image quality, (a) 3 readers independently scored subjective image quality on a 4-point scale and (b) a region-of-interest approach was used to obtain a quantitative estimate of image quality in terms of noise. For lesion detectability, (a) the readers independently counted the number of hypermetabolic lesions and (b) signal-to-noise ratio and contrast-to-noise ratio were computed in a region-of-interest approach. Moreover, the mean and maximal standardized uptake value (SUV mean and SUV max, respectively) of the hypermetabolic lesions was compared across all acquisition times.
RESULTS: For image quality, subjective image quality significantly declined from 8 to 2 mpb (P <; 0.05), with the exception of the difference between 6 and 8 mpb. Image noise increased with shorter imaging duration, ranging from 13% on average in the 8-mpb scans to 23% in the 2-mpb scans (differences were statistically significant for 2 vs 6 mpb, 2 vs 8 mpb, and 4 vs 8 mpb; P <; 0.05). For lesion detectability, 39 hypermetabolic lesions were identified by consensus. There was no difference in detected lesions across all acquisition times. Signal-to-noise ratio and contrast-to-noise ratio were constantly high and did not differ significantly across the acquisition times. The SUV mean and SUV max did not differ significantly across all acquisition times.
CONCLUSIONS: Positron emission tomography acquisition times on integrated PET/MRI do not need to exceed usual acquisition times on current PET/computed tomography scanners: Although the PET image quality suffers from short acquisition times, even a duration of 2 mpb permits sufficient lesion detection. Moreover, quantitative measures of tracer uptake are also reasonably precise at short acquisition times.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23399811     DOI: 10.1097/RLI.0b013e3182823695

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  8 in total

1.  Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.

Authors:  Julian Kirchner; Cornelius Deuschl; Bernd Schweiger; Ken Herrmann; Michael Forsting; Christian Buchbender; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-22       Impact factor: 9.236

2.  Optimized workflow and imaging protocols for whole-body oncologic PET/MRI.

Authors:  Shirou Ishii; Takamitsu Hara; Takeyuki Nanbu; Hiroki Suenaga; Shigeyasu Sugawara; Daichi Kuroiwa; Hirofumi Sekino; Masayuki Miyajima; Hitoshi Kubo; Noboru Oriuchi; Hiroshi Ito
Journal:  Jpn J Radiol       Date:  2016-10-06       Impact factor: 2.374

3.  Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?

Authors:  Benedikt M Schaarschmidt; Johannes Grueneisen; Martin Metzenmacher; Benedikt Gomez; Thomas Gauler; Christian Roesel; Philipp Heusch; Verena Ruhlmann; Lale Umutlu; Gerald Antoch; Christian Buchbender
Journal:  Eur Radiol       Date:  2016-05-14       Impact factor: 5.315

4.  Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.

Authors:  Benedikt Michael Schaarschmidt; Philipp Heusch; Christian Buchbender; Marcus Ruhlmann; Christoph Bergmann; Verena Ruhlmann; Marc Schlamann; Gerald Antoch; Michael Forsting; Axel Wetter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-06       Impact factor: 9.236

5.  Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.

Authors:  Julian Kirchner; Lino Morris Sawicki; Saravanabavaan Suntharalingam; Johannes Grueneisen; Verena Ruhlmann; Bahriye Aktas; Cornelius Deuschl; Ken Herrmann; Gerald Antoch; Michael Forsting; Lale Umutlu
Journal:  PLoS One       Date:  2017-02-22       Impact factor: 3.240

6.  A novel rabbit fixator made of a thermoplastic mask for awake imaging experiments.

Authors:  Rencai Lu; Li Hou; Siyu Wang; Bo She; Hong He; Wentao Gao; Sidang Wang; Dongdong Xv; Yunhai Ji; Shasha Yang; Zhaohui Yang; Shaobo Wang
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

7.  Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer.

Authors:  Susanne Lütje; Sebastian Blex; Benedikt Gomez; Benedikt M Schaarschmidt; Lale Umutlu; Michael Forsting; Walter Jentzen; Andreas Bockisch; Thorsten D Poeppel; Axel Wetter
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

8.  Towards fast whole-body PET/MR: Investigation of PET image quality versus reduced PET acquisition times.

Authors:  Maike E Lindemann; Vanessa Stebner; Alexander Tschischka; Julian Kirchner; Lale Umutlu; Harald H Quick
Journal:  PLoS One       Date:  2018-10-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.